JP2016523910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523910A5 JP2016523910A5 JP2016524170A JP2016524170A JP2016523910A5 JP 2016523910 A5 JP2016523910 A5 JP 2016523910A5 JP 2016524170 A JP2016524170 A JP 2016524170A JP 2016524170 A JP2016524170 A JP 2016524170A JP 2016523910 A5 JP2016523910 A5 JP 2016523910A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- antigen binding
- seq
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims description 160
- 108091000831 antigen binding proteins Proteins 0.000 claims description 160
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 238000013262 cAMP assay Methods 0.000 claims description 22
- 238000003556 assay Methods 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 108010000239 Aequorin Proteins 0.000 claims description 8
- 108091006027 G proteins Proteins 0.000 claims description 8
- 102000030782 GTP binding Human genes 0.000 claims description 8
- 108091000058 GTP-Binding Proteins 0.000 claims description 8
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 230000011664 signaling Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 102000011690 Adiponectin Human genes 0.000 claims description 2
- 108010076365 Adiponectin Proteins 0.000 claims description 2
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 230000008485 antagonism Effects 0.000 claims description 2
- 230000036772 blood pressure Effects 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000005265 energy consumption Methods 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839458P | 2013-06-26 | 2013-06-26 | |
| US61/839,458 | 2013-06-26 | ||
| PCT/US2014/044164 WO2014210205A1 (en) | 2013-06-26 | 2014-06-25 | Cb1 receptor antigen-binding proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018159121A Division JP2018201516A (ja) | 2013-06-26 | 2018-08-28 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523910A JP2016523910A (ja) | 2016-08-12 |
| JP2016523910A5 true JP2016523910A5 (cg-RX-API-DMAC7.html) | 2017-06-29 |
| JP6562912B2 JP6562912B2 (ja) | 2019-08-21 |
Family
ID=51177217
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524170A Active JP6562912B2 (ja) | 2013-06-26 | 2014-06-25 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2018159121A Withdrawn JP2018201516A (ja) | 2013-06-26 | 2018-08-28 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2020152622A Active JP7018104B2 (ja) | 2013-06-26 | 2020-09-11 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2021201683A Withdrawn JP2022037087A (ja) | 2013-06-26 | 2021-12-13 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2023145208A Withdrawn JP2023171760A (ja) | 2013-06-26 | 2023-09-07 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2025103642A Pending JP2025163008A (ja) | 2013-06-26 | 2025-06-19 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018159121A Withdrawn JP2018201516A (ja) | 2013-06-26 | 2018-08-28 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2020152622A Active JP7018104B2 (ja) | 2013-06-26 | 2020-09-11 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2021201683A Withdrawn JP2022037087A (ja) | 2013-06-26 | 2021-12-13 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2023145208A Withdrawn JP2023171760A (ja) | 2013-06-26 | 2023-09-07 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2025103642A Pending JP2025163008A (ja) | 2013-06-26 | 2025-06-19 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10227406B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3013860B1 (cg-RX-API-DMAC7.html) |
| JP (6) | JP6562912B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014302410B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2915386A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014210205A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6598844B2 (ja) | 2014-03-27 | 2019-10-30 | バード・ロック・バイオ・インコーポレイテッド | ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体 |
| WO2017058771A1 (en) * | 2015-09-30 | 2017-04-06 | Bird Rock Bio, Inc. | Antibodies that bind human cannabinoid 1 (cb1) recetor |
| CA3066733A1 (en) | 2017-06-09 | 2018-12-13 | President And Fellows Of Harvard College | Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders |
| CA3076630A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | Transthyretin immunoglobulin fusions |
| KR20210005051A (ko) | 2018-04-30 | 2021-01-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 카나비노이드 수용체 유형 1 (cb1) 결합 단백질들과 이의 용도 |
| JP7430624B2 (ja) | 2020-11-27 | 2024-02-13 | 株式会社ブリヂストン | タイヤ組立体 |
| WO2022164239A1 (ko) | 2021-01-28 | 2022-08-04 | 주식회사 파미노젠 | 피라졸-카르복스아미드 유도체 화합물 및 이의 용도 |
| EP4534672A1 (en) * | 2022-06-03 | 2025-04-09 | Shionogi & Co., Ltd | Antibody that binds to cannabinoid type 1 receptors |
| WO2024022478A1 (zh) * | 2022-07-28 | 2024-02-01 | 长春金赛药业有限责任公司 | 结合大麻素受体cb1的抗体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023232A2 (en) * | 2003-09-04 | 2005-03-17 | Affibody Ab | Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders. |
| US7655685B2 (en) * | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| CA2747807A1 (en) * | 2008-12-23 | 2010-07-01 | Bernard R. Neustadt | Pyrimidine derivatives and methods of use thereof |
| WO2011072336A1 (en) * | 2009-12-18 | 2011-06-23 | The University Of Sydney | Antiviral agents |
-
2014
- 2014-06-25 JP JP2016524170A patent/JP6562912B2/ja active Active
- 2014-06-25 AU AU2014302410A patent/AU2014302410B2/en active Active
- 2014-06-25 CA CA2915386A patent/CA2915386A1/en active Pending
- 2014-06-25 US US14/899,551 patent/US10227406B2/en active Active
- 2014-06-25 EP EP14739018.1A patent/EP3013860B1/en active Active
- 2014-06-25 WO PCT/US2014/044164 patent/WO2014210205A1/en not_active Ceased
-
2018
- 2018-08-28 JP JP2018159121A patent/JP2018201516A/ja not_active Withdrawn
-
2020
- 2020-09-11 JP JP2020152622A patent/JP7018104B2/ja active Active
-
2021
- 2021-12-13 JP JP2021201683A patent/JP2022037087A/ja not_active Withdrawn
-
2023
- 2023-09-07 JP JP2023145208A patent/JP2023171760A/ja not_active Withdrawn
-
2025
- 2025-06-19 JP JP2025103642A patent/JP2025163008A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523910A5 (cg-RX-API-DMAC7.html) | ||
| MX392435B (es) | Anticuerpos estables y solubles que inhiben el vegf. | |
| BR112015022978A2 (pt) | agente de ligação biespecífico, seu método de produção composição farmacêutica, proteína de fusão, uso, sequência de ácido nucleico, vetor, célula hospedeira, método de matar células tumorais e de inibir o crescimento tumoral | |
| SA520411173B1 (ar) | Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137 | |
| JP2014518883A5 (cg-RX-API-DMAC7.html) | ||
| TN2014000536A1 (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| BR112012018914A2 (pt) | "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica." | |
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
| JP2015501814A5 (cg-RX-API-DMAC7.html) | ||
| JP2015525230A5 (cg-RX-API-DMAC7.html) | ||
| JP2012520679A5 (cg-RX-API-DMAC7.html) | ||
| ZA201703241B (en) | Anti-c5 antibodies and methods of use | |
| SA518391704B1 (ar) | C5 أجسام مضادة لـ وطرق لاستخدامها | |
| HRP20151227T1 (hr) | Sastavi i postupci uporabe za terapeutska protutijela | |
| HRP20251020T1 (hr) | Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3 | |
| Adachi et al. | Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies | |
| AR073978A1 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4-humano | |
| MX351682B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| AR086360A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
| BR112012024710A8 (pt) | moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem | |
| MX394165B (es) | Anticuerpos anti-receptor ccr7 humanizados. | |
| BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| MY187848A (en) | Anti-c5 antibodies and methods of use | |
| JP2008530138A5 (cg-RX-API-DMAC7.html) |